SynCore Biotechnology Co.,Ltd

Taipei Exchange 4192.TWO

SynCore Biotechnology Co.,Ltd Return on Assets (ROA) for the year ending December 31, 2023: -10.09%

SynCore Biotechnology Co.,Ltd Return on Assets (ROA) is -10.09% for the year ending December 31, 2023, a 76.65% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • SynCore Biotechnology Co.,Ltd Return on Assets (ROA) for the year ending December 31, 2022 was -43.21%, a 22.32% change year over year.
  • SynCore Biotechnology Co.,Ltd Return on Assets (ROA) for the year ending December 31, 2021 was -55.63%, a -27.45% change year over year.
  • SynCore Biotechnology Co.,Ltd Return on Assets (ROA) for the year ending December 31, 2020 was -43.65%, a 18.41% change year over year.
  • SynCore Biotechnology Co.,Ltd Return on Assets (ROA) for the year ending December 31, 2019 was -53.50%.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
SV Wall Street
Taipei Exchange: 4192.TWO

SynCore Biotechnology Co.,Ltd

CEO Mr. Chih-Wen Lee
IPO Date Aug. 29, 2013
Location
Headquarters 84 Chung Shan Road
Employees 40
Sector Health Care
Industries
Biotechnology Cosmetics Pharmaceuticals
Description

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials. In addition, the company provides SB05-EndoTAG, an conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG and MacuCLEAR Inc.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

StockViz Staff

February 5, 2025

Any question? Send us an email